Company Encyclopedia
View More
name
JENKEM
688356.SH
Jenkem Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of medical and pharmaceutical polyethylene glycol derivative (PEG) products in China and internationally. The company offers high molecular weight polyethylene glycol derivatives comprising branched, methoxylated, bifunctionalized, heterofunctionalized disubstituted, multi-arm, multi-arm heterofunctional disubstituted, amino-polyglycolic, N-terminated polyethylene glycol-modified, and thiol-modified polyethylene glycol PEG products; monodisperse PEG products consisting of methoxy monodisperse PEG derivatives, and monodisperse PEG derivatives with the same functional and heterofunctional groups; click chemistry; lipid nanoparticles delivery system accessories; PEG linkers, such as ADC and PROTAC linkers; PEG medical devices, which include multi-arm PEG derivatives; polyethylene glycol standards; block copolymers; PEG standards; long-acting polypeptide fatty acid side chains, including semaglutide, tirzepatide/icodec, and somapacitan intermediates; and Silkrose injectable cross-linked sodium hyaluronate gel, a passive implantable device used to correct moderate to severe nasolabial folds through subcutaneous injection. It also provides technical services comprising development of synthetic methods, quality research and IND application, analytical method development, and polyethylene glycolization technology services. Jenkem Technology Co., Ltd.
3.155 T
688356.SHMarket value -Rank by Market Cap -/-

Financial Score

10/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking145/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE2.96%C
    • Profit Margin15.04%A
    • Gross Margin78.82%A
  • Growth ScoreC
    • Revenue YoY7.94%B
    • Net Profit YoY-20.89%D
    • Total Assets YoY2.88%C
    • Net Assets YoY2.41%C
  • Cash ScoreB
    • Cash Flow Margin665.07%C
    • OCF YoY7.94%B
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreA
    • Gearing Ratio5.92%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    JENKEM: Currently, the applicable U.S. tariff rate for the company's products has not changed

    JENKEM stated on its interactive platform on October 15 that despite U.S. President Trump announcing high tariffs on various imported products starting October 1, the U.S. tariff rates applicable to the company's products have not changed. The stability of the company's cooperation with U.S. customers is not significantly affected, and it will continue to monitor changes in international trade policies to ensure stable business development

    Zhitong·
    SH
    688356
    +0.21%
    Zhitong·
    SH
    688356
    +0.21%

    A-share innovative drug concept stocks fluctuated lower, with InventisBio falling over 10%. Other stocks such as Huahai Pharmaceutical, JENKEM, Lifeon Pharmaceutical, JOINN, Guangsheng Tang, HitGen, and Baillie Gifford also dropped more than 6%

    Zhitong·
    SH
    688356
    +0.21%
    SH
    603127
    +1.20%
    HK
    06127
    +0.76%
    Zhitong·
    SH
    688356
    +0.21%
    SH
    603127
    +1.20%
    HK
    06127
    +0.76%

    JENKEM: Wu Kaiting plans to reduce his holdings by no more than 2%

    According to the Zhitong Finance APP, JENKEM announced that due to the shareholder's own funding needs, Wu Kaiting plans to reduce his holdings of the company's shares by no more than 1.213 million shares through block trading within three months after the announcement is disclosed, with a proposed reduction ratio not exceeding 2% of the company's total share capital

    Zhitong·
    SH
    688356
    +0.21%
    Zhitong·
    SH
    688356
    +0.21%

    Innovative drug concept stocks are repeatedly active, Chimin hits the daily limit

    Innovative drug concept stocks are repeatedly active, Chimin hit the daily limit, JENKEM rose over 10%, YKYY, Nossan, Frontier Biotechnologies, Salubris, and HitGen followed suit

    Zhitong·
    SH
    688356
    +0.21%
    SH
    688658
    +0.50%
    SH
    688221
    +2.38%
    Zhitong·
    SH
    688356
    +0.21%
    SH
    688658
    +0.50%
    SH
    688221
    +2.38%

    JENKEM: Actively exploring the optimization of existing R&D processes through AI

    JENKEM stated on the interactive platform that it has formed a computational biology team to explore optimizing the R&D process through AI, particularly in key areas such as drug structure design and molecular screening. Although no significant results have been achieved yet, the short-term impact on performance is minimal, but the company is optimistic about the potential of AI in improving R&D efficiency and reducing costs

    Zhitong·
    SH
    688356
    +0.21%
    Zhitong·
    SH
    688356
    +0.21%
    © 2025 Longbridge｜Disclaimer